在研广谱头孢菌素类抗生素的新进展
. 890 .
[22] Toda A, Ohki H, Yamanaka T, et al. Synthesis and SAR
of novel parenteral anti-pseudomonal cephalosporins: Discovery of FR264205[J]. Bioorg Med Chem Lett, 2008, 18 (17): 4849-4852.
[23] Calixa Therapeutics Inc. Calixa Therapeutics announces
positive Phase 1 results for CXA-101, a novel intravenous cephalosporin antibiotic with excellent anti-pseudomonal activity [EB/OL]. (2009-03-24) [2009-09-26] doc.guandang.net. calixainc.com/PR/Calixa%20Press%20Release%20March%2024%202009.pdf.
[24] Calixa Therapeutics Inc. Calixa Therapeutics announces
initiation of Phase 2 clinical trial of its antibiotic, CXA-101, in patients with complicated urinary tract infections [EB/OL]. (2009-07-30) [2009-09-26] doc.guandang.net.
[25] Page M G P, Heim J. New molecules from old classes:
Revisiting the development of β-lactams[J]. IDrugs, 2009, 12 (9): 561-565.
[26] Takeda S, Nakai T, Wakai Y, et al. In vitro and in vivo
activities of a new cephalosporin, FR264205 against Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 2007, 51 (3): 826-830.
[27] Cubist Pharmaceuticals, Inc. Cubist Pharmaceuticals
to acquire Calixa Therapeutics [EB/OL]. (2009-12-14) [2010-01-22] doc.guandang.net linkx/file.aspx?IID=4093793&FID=8747721.
[28] Calixa Therapeutics Inc. Calixa Therapeutics to make
multiple presentations on CXA-101 and CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy [EB/OL]. (2009-09-15) [2009-09-26] doc.guandang.net.
[29] Giske C G, Ge G, Nordmann P. Activity of cephalosporin
CXA-101 (FR264205) and comparators against extended-spectrum-β-lactamase-producing Pseudomonas aeruginosa[J]. J Antimicrob Chemother, 2009, 64 (2): 430-431.
[30] Vergidis P I, Falagas M E. Multidrug-resistant gram-negative
bacterial infections: The emerging threat and potential novel treatment options[J]. Curr Opin Investig Drugs, 2008, 9 (2):176-183.
[31] Takeda S, Ishii Y, Hatano K, et al. Stability of FR264205
在研广谱头孢菌素类抗生素的新进展 崔玉彬等
against AmpC β-lactamase of Pseudomonas aeruginosa[J]. Int J Antimicrob Agents, 2007, 30 (5): 443-445.
[32] Livermore D M, Mushtaq S, Ge Y, et al. Activity of
cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates[J]. Int J Antimicrob Agents, 2009, 34 (5): 402-406.[33] Takeda S, Ikeda F, Hatano K. In vitro antibacterial activity
of a new cephalosporin, FR295389, against IMP-type metallo-β-lactamase-producers[J]. J Antibiot, 2008, 61 (1): 36-39.
[34] Murano K, Yamanaka T, Toda A, et al. Structural
requirements for the stability of novel cephalosporins to AmpC β-lactamase based on 3D-structure[J]. Bioorg Med Chem, 2008, 16 (5): 2261-2275.
[35] Glinka T W, Cho A, Zhang Z J, et al. SAR studies of anti-MRSA non- zwitterionic 3-heteroarylthiocephems[J]. J Antibiot, 2000, 53 (10): 1045-1052.
[36] Shahid M, Sobia F, Singh A, et al. Beta-lactams and beta-lactamase-inhibitors in current- or potential- clinical practice: A comprehensive update[J]. Crit Rev Microbiol, 2009, 35 (2): 81-108.
[37] Hoffman-Roberts H L, Babcock E C, Mitropoulos IF.
Investigational new drugs for the treatment of resistant pneumococcal infections[J]. Expert Opin Investig Drugs, 2005, 14 (8): 973-995.
[38] Malouin F, Blais J, Chamberland S, et al. RWJ-54428
(MC-02,479), a new cephalosporin with high af nity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal beta-lactamases[J]. Antimicrob Agents Chemother, 2003, 47 (2): 658-664.
[39] Swenson J M, Tenover F C. In vitro activity of a new
cephalosporin, RWJ-54428, against streptococci, enterococci and staphylococci, including glycopeptides- intermediate Staphylococcus aureus[J]. J Antimicrob Chemother, 2002, 49 (5): 845-850.
[40] Johnson A P, Warner M, Carter M, et al. In vitro activity of
cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant gram-positive cocci[J]. Antimicrob Agents Chemother, 2002, 46 (2): 321-326.
[41] Chamberland S, Blais J, Hoang M, et al. In vitro activities
of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria[J]. Antimicrob Agents Chemother, 2001, 45 (5): 1422-1430.
笔者查阅了近几年关于头孢菌素类抗生素的研究文献, 对其最新进展及研究热 点作...Kazuko 等 [ 1] 报道了广谱抗菌的头孢烯酸类化合物 C- 01, 结构通式见表 ...
头孢菌素类抗生素的最新研究进展薛雨 陈宇瑛* (中国医药集团总公司四川抗菌素...第一代头孢菌素[3-4]是上世纪60年代及70年代初 开发的,多为半广谱抗生素,...
头孢菌素类抗生素研究进展-sn_药学_医药卫生_专业资料。头孢菌素及头霉素类抗生...头孢菌素又称先锋霉素,是一类广谱半合成抗生素,第一个头孢菌素在20世纪60年代...
石河子大学 药物分析专题论文头孢菌素类抗生素的研究进展及应用 姓名:魏璐璐学号:...第 一代头孢菌素类药物多为半广谱抗菌药物,对金黄色葡萄球菌产生的青霉素酶稳定...
头孢菌素类抗生素的最新研究进展---重点参考_医药卫生_专业资料。头孢菌素类抗生...多 为半 广谱抗生素, 耐青 霉素酶 ,对革兰 阳性菌( 括耐 青霉 素 的...
在研广谱头孢菌素类抗生... 12页 免费头孢菌素类抗生...ar/I 参考文献 []学儒.孢菌素临床应用进展.学理论与实践 1徐头医[,9586:4...
头孢菌素类药物研究进展_医药卫生_专业资料。头孢菌素类药物研究进展 摘 要: 头孢...头孢吡普为广谱头孢菌素类药物,其抗菌谱包 括 MRSA、万古霉素中度耐药金黄色...
头孢菌素类抗生素研究进展-sn - 副本_医药卫生_专业资料。Logo 头孢菌素类抗生...属于深谱、广谱抗生素; ? 增强头孢哌酮对葡萄球菌属、假单胞菌属等 的活性;...
11 头孢菌素类抗菌药研究进展分析报告 头孢菌素类抗菌药研究进展分析报告 研究...第一代头孢菌素是上世纪 60 年代及 70 年代初开发的,多为半广谱抗生素, 耐...
热门文档